Article Text

PDF
Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions
  1. N Nigam,
  2. J Hedaya,
  3. W R Freeman
  1. UCSD Department of Ophthalmology, Shiley Eye Center, Joan and Irwin Jacobs Retina Center, La Jolla, CA, USA
  1. Dr W R Freeman, UCSD Department of Ophthalmology, Shiley Eye Center, 0946, Joan and Irwin Jacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA 92037, USA; freeman{at}eyecenter.ucsd.edu

Statistics from Altmetric.com

We read with great interest the article “Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions,” by Lux et al.1 Avastin and Lucentis have become the standard of care for choroidal neovascularisation with a better visual acuity outcome than other well-studied therapies.2 3 The use of Macugen and photodynamic therapy (PDT) is declining rapidly. The current challenge with the new anti-vascular endothelial growth factor treatment is to determine which eyes do and do not respond to …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Mailbox
    A Lux H Llacer F M A Heussen A M Joussen